GLP-1 access guide
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide is not FDA-approved. FDA does not review compounded drugs for safety, effectiveness or quality before marketing through the drug-approval process. Approval of Wegovy or Ozempic does not extend to a pharmacy’s compounded preparation, and a licensed or registered facility does not make that preparation an FDA-approved generic. [1][2]
Approval belongs to the finished drug
FDA’s approval process evaluates evidence and proposed labeling for a specific drug and intended use. It is not a general approval of every product sharing an ingredient heading. A compounder’s preparation is a separate finished product from the branded package. This is why saying semaglutide appears in an approved drug cannot establish that an unrelated compounded semaglutide preparation has undergone the same approval process. [2]
The distinction is about the regulatory evidence, not a conclusion about how an individual patient will respond. This publisher does not assess a compounded prescription’s clinical suitability or compare patient outcomes. We report the agency’s approval-status definition so a reader can understand what an advertisement does and does not establish. Clinical questions belong with the prescribing professional. [1]
A licensed pharmacy is not a product approval
State pharmacy licensing concerns the entity providing pharmacy services. FDA outsourcing-facility registration concerns a different regulated category. Neither record is an FDA approval for each compounded preparation produced there. A company can make an accurate licensing or registration statement while the medication it discusses remains unapproved. Keep those statements separate when reading the service’s description. [3][4]
Check a claimed license through the relevant state board and a claimed outsourcing registration through FDA’s current facility list. Match the legal entity and location. Those checks answer identity and category questions, not whether a particular semaglutide product has an approved drug application. A storefront badge or similar company name should not be used as a substitute for the appropriate official record. [5][4]
Compounded and generic are different terms
FDA’s compounding questions explicitly distinguish compounded drugs from approved generics. An approved generic must satisfy its approval pathway, including the relevant active ingredient, strength, dosage form, route and bioequivalence requirements. The word generic therefore cannot accurately be used as a shortcut for every lower-priced compounded prescription. Ask which category the advertised offer actually belongs to. [6][1]
A provider saying its preparation is like a brand or contains a familiar ingredient does not supply an FDA therapeutic-equivalence determination. The directory organizes offers by the medication names recorded in primary sources but does not transform that organization into a substitution claim. The pharmacist can identify the actual finished product, and the clinician handles the patient’s prescribing decision. [6][5]
Conditional compounding exemptions do not create approval
FDA explains that 503A and 503B can exempt qualifying compounded drugs from specified requirements when their conditions are met. An exemption from premarket approval is not the same as completing the approval process. The legal-framework question and the approval-status question therefore have different answers: a compounded preparation may require a conditional analysis while remaining unapproved. [7][3]
The current semaglutide context is also post-shortage. FDA’s April 2026 reminder states that semaglutide is not on the shortage or 503B bulks lists and describes copy and bulk restrictions. Meeting any applicable conditions would not turn a compounded preparation into Wegovy, Ozempic or an FDA-approved generic. Likewise, approval of a brand does not answer whether a proposed compound qualifies under those conditions. [8]
Added ingredients and route claims need their own identification
A combination labeled semaglutide plus B12 is not an approved semaglutide brand merely because the additional ingredient is familiar. FDA’s compounded-semaglutide notice discusses added ingredients and says the safety and effectiveness of such combinations has not been established. We report that evidence-status statement without recommending an additive or presenting a company’s claimed benefit as a clinical finding. [9]
A different route of administration also should not inherit the approval of another finished product. A provider’s sublingual compounded offer and a manufacturer’s approved oral tablet are distinct descriptions. The presence of an oral category in an advertisement does not tell the reader which preparation has an FDA approval record. Ask for the full product name, formulation and dispensing pharmacy when the category is unclear. [10][2]
How to use this answer when researching a provider
Read the provider’s approval statement alongside its exact offering label and source date. A directory row describing a compounded program is evidence of a recorded advertisement, not an FDA endorsement or a clinical recommendation. Our formulation tables keep these labels visible so cost comparisons do not erase the regulatory category. A price or subscription term supplies financial information, not approval evidence. [10][11][12][1]
If a service presents a compounded product as FDA-approved, ask it to identify the actual finished product and approval record it means. Do not settle the issue through a generic ingredient description or a facility registration number. FDA’s February 2026 enforcement announcement discusses misleading promotion of unapproved GLP-1 preparations. The relevant question is the preparation’s documented status, not the confidence of the marketing language. [13][2]
An enforcement announcement is another distinct record
FDA’s February 2026 announcement describes intended action involving unapproved GLP-1 ingredients and misleading mass-marketing claims. It is an enforcement-policy announcement, not an approval record for a compounded product and not a private verdict on every pharmacy listed in this directory. Keep the source’s stated scope and date with the claim. A reader checking approval should look for the exact finished product rather than infer its status from whether a company has changed its marketing after an announcement. [13]
The same distinction applies to quality documentation a pharmacy might provide. A certificate, facility inspection or laboratory result can concern a particular ingredient, facility or preparation, but it is not the FDA drug-approval process. Ask what the document actually covers. Describing a product as tested does not answer whether the finished medicine has an FDA approval record. [2][1]
Additional reading from a provider
These pages describe a provider’s perspective or its own service. The official documents cited in this guide establish regulatory, approval and program facts.
- Gentle Health: provider verification checklist (provider-authored)
Gentle’s verification checklist distinguishes a pharmacy license from approval of a compounded product; FDA above establishes the approval status.
Checked
Sources
Sources are checked on the dates shown. Official documents establish product and program rules; provider sources describe their own offers and the additional reading identified above. Provider catalog examples retain their original price-check dates; this article’s preparation date does not refresh them.
- FDA: compounding questions and answers — checked .
- FDA: development and approval process for drugs — checked .
- FDA: provisions applying to 503A and 503B compounding — checked .
- FDA: registered outsourcing facilities — checked .
- FDA BeSafeRx: online pharmacy questions — checked .
- FDA: generic drug facts and approval requirements — checked .
- FDA: human drug compounding laws — checked .
- FDA: compounding policies as GLP-1 supply stabilizes — checked .
- FDA: compounded semaglutide product differences and added ingredients — checked .
- Gentle Health: advertised formulations and clinical process — checked .
- Trimi: compounded semaglutide and tirzepatide programs — checked .
- Cora Health: recorded medication programs — checked .
- FDA: February 2026 enforcement announcement for unapproved GLP-1 marketing — checked .
- Gentle Health: provider verification checklist (provider-authored) — checked .